Based on these data, and evidence of clinical activity in patients with advanced pancreatic cancer, a clinical study of elraglusib, an anti-PD-1 mAb and chemotherapy is ongoing (NCT NCT05239182). The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.